|Positive WB detected in||mouse small intestine tissue, human placenta tissue|
|Positive IHC detected in||human kidney tissue, human cervical cancer tissue|
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
|Western Blot (WB)||WB : 1:500-1:2400|
|Immunohistochemistry (IHC)||IHC : 1:20-1:200|
|Sample-dependent, check data in validation data gallery|
12166-1-AP targets Dysadherin in WB, IHC,ELISA applications and shows reactivity with human, mouse samples.
|Tested Reactivity||human, mouse|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Dysadherin fusion protein Ag2808|
|Full Name||FXYD domain containing ion transport regulator 5|
|Calculated molecular weight||178 aa, 19 kDa|
|Observed molecular weight||24 kDa|
|GenBank accession number||BC009642|
|Gene ID (NCBI)||53827|
|Purification Method||Antigen affinity purification|
|Storage Buffer||PBS with 0.02% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.|
Dysadherin, also known as FXYD5 (FXYD domain containing ion transport regulator 5), is a cancer-associated cell membrane glycoprotein which belongs to the FXYD family. The FXYD family, which contains seven members, are tissue specific regulators of the Na,K-ATPase. Dysadherin is involved in down-regulation of E-cadherin, which plays important roles in tumor development and metastasis. It is present in spleen, lung, skeletal muscle, and testis. Increased expression of dysadherin has been associated with increased cell motility and metastatic potential.
Development and Clinical Validation of a Seven-Gene Prognostic Signature Based on Multiple Machine Learning Algorithms in Kidney Cancer.
Int J Oncol
A FXYD5/TGF‑β/SMAD positive feedback loop drives epithelial‑to‑mesenchymal transition and promotes tumor growth and metastasis in ovarian cancer.